Definium Therapeutics (NASDAQ:DFTX) Stock Rated Overweight in New Coverage at JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. began coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report released on Friday, Briefing.com reports. The firm set an “overweight” rating and a $84.00 price target on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 145.76% from the company’s previous close.

Several other research firms also recently weighed in on DFTX. Royal Bank Of Canada reissued an “outperform” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research report on Friday, September 11th. Robert W. Baird raised their target price on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Maxim Group set a $55.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, Bank of America started coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $66.00.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $34.18 on Friday. The stock’s fifty day simple moving average is $40.43 and its 200 day simple moving average is $32.95. The stock has a market capitalization of $4.59 billion, a price-to-earnings ratio of -9.96 and a beta of 2.19. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a 52-week low of $10.46 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, sell-side analysts forecast that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,377 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the transaction, the chief financial officer owned 394,528 shares in the company, valued at $14,427,888.96. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the company’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the completion of the transaction, the insider directly owned 359,036 shares in the company, valued at approximately $13,129,946.52. The trade was a 0.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 71,098 shares of company stock worth $2,626,115. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock valued at $59,000 after purchasing an additional 343 shares during the last quarter. Nykredit A S bought a new stake in Definium Therapeutics during the 2nd quarter valued at approximately $45,000. Allworth Financial LP acquired a new stake in Definium Therapeutics in the 2nd quarter valued at approximately $110,000. Integrated Wealth Concepts LLC bought a new position in Definium Therapeutics in the 2nd quarter worth approximately $159,000. Finally, NewEdge Advisors LLC bought a new position in Definium Therapeutics in the 2nd quarter worth approximately $222,000. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.